polb

POLB (DNA polymerase beta)

The dedicated short-patch base-excision-repair (BER) polymerase in mammals. POLB performs two indispensable chemical steps after ape1 cleaves an abasic site: it removes the 5’-deoxyribose-phosphate (dRP) flap via its lyase activity and fills the resulting single-nucleotide gap via its polymerase activity. No other mammalian polymerase combines both activities, making POLB non-redundant for short-patch BER. POLB expression and activity decline measurably in aged nervous tissue, implicating BER insufficiency as a contributor to age-related genomic instability.

Identity

• UniProt: P06746 (DPOLB_HUMAN)
• NCBI Gene: 5423
• HGNC symbol: POLB
• Ensembl: ENSG00000070501
• Length: 335 amino acids (~39 kDa total)
• Family: X-family DNA polymerases (alongside POLM, POLL, TdT)
• GenAge entry: GenAge ID 236 (confirmed 2026-05-07; listed as candidate aging-related gene based on mouse haploinsufficiency cancer/aging evidence)
• Mouse ortholog: Polb (one-to-one ortholog; highly conserved)

Domain architecture

POLB is a bimodular enzyme with two functionally independent domains joined by a flexible linker ¹:

Domain	Residues (approx.)	Activity
N-terminal 8-kDa domain	1–87	dRP lyase; ssDNA binding
31-kDa polymerase domain	88–335	DNA synthesis; thumb, palm, fingers sub-domains

The 8-kDa lyase domain forms a Schiff-base intermediate between Lys-72 and the deoxyribose C1’ of the 5’-dRP group, followed by beta-elimination to release the flap as a dRP-Lys adduct and regenerate free Lys-72. This chemistry is unique among mammalian polymerases. unsourced — Beard & Wilson 2003 (Structure) covers polymerase fidelity structure broadly and does not describe this lyase mechanism; citation needs replacement with the appropriate primary source (e.g., Prasad et al. 1998 Biochemistry or Beard & Wilson 2000 Mutat Res).

The 31-kDa polymerase domain adopts the classical right-hand (thumb/palm/fingers) fold of X-family polymerases. On single-stranded templates POLB synthesis is distributive, but short DNA gaps with a 5’ phosphate are filled processively to completion ² — a property well-suited to the defined gap substrates generated by APE1 in short-patch BER.

Function in short-patch BER

Short-patch BER is the predominant repair pathway for oxidised, alkylated, or deaminated single bases. POLB occupies the central two steps ²:

1. APE1 cleaves the phosphodiester backbone 5’ to the abasic site, leaving a 3’-OH and a 5’-dRP flap.
2. POLB dRP lyase (8-kDa domain) removes the 5’-dRP flap — this is the rate-limiting step in short-patch BER.
3. POLB polymerase (31-kDa domain) adds a single nucleotide to the 3’-OH, filling the gap.
4. LIG3/XRCC1 seals the resulting nick.

POLB operates as a monomer; it does not form homodimers or require cofactor subunits. Its processive synthesis length is limited to ~1 nt under short-patch conditions; longer fills (2–10 nt) engage the long-patch BER sub-pathway via PCNA-dependent polymerases (POLD/POLE).

POLB forms a functional complex — often called the “passing the baton” BER machine — with xrcc1, lig3, and ape1 to coordinate hand-off of repair intermediates without releasing the damaged strand ³.

Fidelity

POLB has low fidelity compared to replicative polymerases — it lacks an intrinsic 3’→5’ proofreading exonuclease. The Beard & Wilson 2003 Structure review confirms POLB as a low-fidelity X-family polymerase (kpol ~10 s⁻¹ for correct dCTP insertion, Table 1 of that paper) ¹; a commonly cited misincorporation rate of ~10⁻⁴ (one error per 10,000 insertions) derives from other kinetic studies of the Wilson group and is not explicitly stated in Beard & Wilson 2003. unsourced — cite the primary kinetic study (e.g., Beard & Wilson 1995 Biochemistry) for the 10⁻⁴ figure. Under normal conditions, low fidelity is tolerable because errors in single-nucleotide BER gaps are subject to downstream mismatch or other surveillance pathways, and BER substrates are predominantly non-coding lesions. BER variants with further-reduced fidelity have been identified in cancer tissue.

Role in aging

POLB knockout is embryonic lethal

Complete loss of POLB causes embryonic death at approximately E10.5 in mice ², establishing that POLB is essential for mammalian development and cannot be compensated by other polymerases. This also means lifespan-extension genetic studies using full knockouts are not possible; heterozygous models are the primary tool.

Dimension	Status	Notes
Pathway conserved in humans?	yes	BER is highly conserved; POLB is the sole mammalian short-patch dRP lyase
Phenotype (haploinsufficiency) conserved in humans?	partial	Down syndrome as a POLB haploinsufficiency model shows accelerated BER deficits; direct human heterozygous studies lacking
Replicated in humans?	no	No germline POLB heterozygous human cohort studied; Down syndrome is an indirect model

Heterozygous POLB+/- mice: increased cancer and modest aging acceleration

POLB+/- mice (one functional allele; male-only C57BL/6 cohort, n=60 wild-type and n=67 heterozygous) maintain ~50% lower β-pol transcript and protein levels throughout life and show elevated lymphoma (6.7-fold increase; OR 6.7 ± 0.77, P < 0.007) and adenocarcinoma incidence (2.7-fold increase, P < 0.05) with age, along with a modest but significant acceleration of age-dependent mortality (P < 0.05) ⁴. This links partial BER insufficiency directly to age-dependent cancer risk, supporting the genomic-instability hallmark. needs-human-replication

Down syndrome, in which chromosome 21 trisomy disrupts folate metabolism and indirectly reduces POLB-mediated BER, has been proposed as a model of POLB haploinsufficiency and accelerated aging ⁵. BER intermediates accumulate in DS brains and the oxidative burden from trisomy-21 gene-dosage effects compounds the repair deficit. needs-replication — causal interpretation is confounded by chromosome 21 dosage effects beyond POLB.

POLB activity declines in aged nervous tissue

In rat cerebral cortex neuronal extracts, DNA gap-repair capacity is substantially reduced in aged animals. Adding recombinant POLB and DNA ligase to aged extracts restores repair activity to young-animal levels ⁶. This identifies POLB — rather than upstream damage-recognition steps — as a rate-limiting factor in aged neurons, consistent with declining BER in aging brain being a downstream effect of POLB loss/inactivation rather than substrate inaccessibility. needs-human-replication

The mechanism of age-related POLB decline is not fully established. Candidate mechanisms include transcriptional downregulation, oxidative modification of Lys-72 (the active-site nucleophile), and changes in the XRCC1 scaffolding complex abundance.

Mitochondrial BER role

POLB also participates in mitochondrial base excision repair. Mitochondrial extracts from Polb-/- mouse embryonic fibroblasts and purified-protein comparisons show that POLB outperforms POLG at mitochondrial single-nucleotide gap-filling: POLB achieved complete gap-filling within 1 minute at 3 nM, while POLG required 10 nM and left unfilled gaps even after 30 minutes ⁷. Mitochondrial extracts lacking POLB show dramatically decreased BER incorporation capacity. This implicates POLB in maintaining mitochondrial genome integrity under oxidative stress, potentially linking POLB activity to mitochondrial-dysfunction. no-mechanism — the import mechanism by which POLB (which lacks a canonical mitochondrial targeting sequence) localizes to mitochondria is not resolved in Baptiste 2021 or the broader literature.

Pathway membership

• base-excision-repair — executes dRP lyase + gap-fill steps after APE1 incision; rate-limiting role
• dna-damage-response — integrated downstream of damage-recognition and APE1 incision

Key interactors

• xrcc1 — scaffold for short-patch BER complex; stimulates POLB activity and recruits LIG3
• lig3 — seals the nick after POLB gap-filling in short-patch BER
• ape1 — directly hands off the nicked substrate to POLB (“baton-passing” model)
• pcna — required for long-patch BER but not short-patch; PCNA-POLB interaction coordinates pathway choice
• PRMT6 — methylates POLB Arg residues, enhancing polymerase activity (not yet a wiki page)
• HUWE1, STUB1/CHIP, USP47 — regulate POLB stability via ubiquitination (specific residues reported in literature include Lys-41 and Lys-61; frontmatter also lists Lys-72 acetylation) unsourced — ubiquitination site assignments need primary citation; note discrepancy with frontmatter key-ptms field (lists Lys61-ubiquitination, Lys72-acetylation but not Lys-81)

Druggability

Aging-context tier: 4 (undruggable in aging-indication context). Open Targets Platform (ENSG00000070501) reports “High-Quality Ligand” and “Structure with Ligand” tractability for small molecules — confirming that research-grade POLB inhibitors exist (e.g., pamoic acid, NSC-666715, developed to potentiate alkylating chemotherapy). However, no clinical drug targets POLB for any indication, and no aging-indication-validated POLB modulator exists. Per wiki convention, aging-context tier reflects whether an aging-validated clinical modulator exists, not maximum-druggability across all indications; max-druggability is tier 2–3 (high-quality probe), but aging-context is tier 4.

The therapeutic logic in aging runs in the opposite direction: POLB activation or stabilization might be desired (to restore declining BER capacity in aged tissue), but no such activator has advanced to the clinic.

Germ-line variation and human evidence

No Mendelian randomization study has examined POLB germline variants as instruments for aging outcomes; mr-causal-evidence: not-tested reflects absence of published instruments rather than negative result. Natural POLB variants in gastric and colorectal cancer tissue (identified post-somatically) show impaired BER capacity, consistent with POLB as a gatekeeper, but these are somatic not germline findings. unsourced — somatic variant catalog citation needed; check COSMIC; the prior citation to Sobol 1996 here was incorrect (Sobol 1996 is a mouse knockout study and does not describe human somatic cancer variants).

Limitations and knowledge gaps

• No human heterozygous cohort. All haploinsufficiency aging data come from mice; the POLB+/- human phenotype is unknown.
• Age-decline mechanism unresolved. Whether declining POLB activity in aged tissue reflects reduced transcription, protein oxidation, altered complex stoichiometry, or post-translational modification changes is not established. no-mechanism
• Mitochondrial import mechanism. How POLB (no canonical MTS) accesses mitochondria is disputed. no-mechanism
• GTEx aging correlation not populated. gtex-aging-correlation: null — retrieve from GTEx v8 using ENSG00000070501; see sops/finding-tissue-expression.md. unsourced
• GenAge listed. POLB is GenAge ID 236; listed as a candidate aging-related gene based on haploinsufficiency mouse evidence. The genage-id: null frontmatter was incorrect and has been corrected.
• Long-patch BER interaction quantification. The fraction of POLB’s total cellular BER contribution that comes from mitochondrial vs nuclear short-patch vs long-patch is not precisely established in aged vs young tissue.

Footnotes

Footnotes

1. doi:10.1016/s0969-2126(03)00051-0 · Beard WA, Wilson SH · Structure 2003 · review · model: structural origins of DNA polymerase fidelity across A, B, RT, X, and Y families; POLB (X family) cited as a low-fidelity polymerase with kpol ~10 s⁻¹ for correct dCTP insertion; paper does NOT describe the dRP lyase Schiff-base mechanism — that claim requires a different primary source · PDF: verified ↩ ↩²

2. doi:10.1038/379183a0 · Sobol RW et al. · Nature 1996 · in-vivo (mouse, knockout) · model: POLB-/- embryonic lethal — homozygous embryos do not survive beyond day 10.5 of gestation; POLB-/- fibroblasts show complete loss of BER (uracil-initiated repair); POLB+/- show reduced β-pol protein expression; gap-filling in defined BER substrates is processive · local PDF available ↩ ↩² ↩³

3. doi:10.1016/s0079-6603(01)68097-8 · Tomkinson AE et al. · Prog Nucleic Acid Res Mol Biol 2001 · review · model: mammalian BER ligation; POLB–LIG3–XRCC1 complex coordination · PDF: not_oa no-fulltext-access ↩

4. doi:10.1158/0008-5472.CAN-06-1177 · Cabelof DC et al. · Cancer Research 2006 · in-vivo (mouse) · model: male POLB+/- C57BL/6 (backcrossed ≥18 generations); n=60 (+/+), n=67 (+/-); aged 24–26 months; 50% lower β-pol transcripts and protein maintained throughout life; 6.7-fold lymphoma increase (OR 6.7 ± 0.77, P < 0.007); 2.7-fold adenocarcinoma increase (P < 0.05); 20% +/- animals bore multiple tumors vs 5% +/+ (P < 0.05); modest acceleration of age-dependent mortality rate (P < 0.05) · PDF: verified ↩

5. doi:10.1016/j.mad.2011.10.001 · Patterson D, Cabelof DC · Mech Ageing Dev 2012 · review · model: Down syndrome as POLB haploinsufficiency / accelerated-aging model · PDF: not_oa no-fulltext-access — claims on this page citing this source are unverified against the full text ↩

6. doi:10.1111/j.1471-4159.2004.02923.x · Krishna TH et al. · J Neurochemistry 2005 · in-vitro (rat neuronal extract, aged vs young) · model: rat cerebral cortex; POLB + LIG3 addition restores aged-extract BER · PDF: not_oa no-fulltext-access — claims on this page citing this source are unverified against the full text ↩

7. doi:10.1016/j.dnarep.2021.103050 · Baptiste BA et al. · DNA Repair 2021 · in-vitro (Polb-/- MEF extracts + purified proteins) · model: Polb-/- mouse embryonic fibroblasts and purified POLβ vs POLγ on synthetic substrates; POLB (3 nM) achieves complete mitochondrial gap-filling in 1 min vs POLG (10 nM) which leaves unfilled gaps at 30 min; mitochondrial extracts from Polb-/- MEFs show dramatically decreased BER · PMC: PMC7887074 (verified via full text; local PDF download failed — green OA via PMC) ↩